| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
MAIA Biotechnology, Inc.$1.44
-0.02 (-1.37%)
D 30Pipeline Score Overvalued Biotech · Clinical
Market Cap
77.82 M
EPS
-0.68
P/E Ratio
-
Value Trade
3.10 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
43.65 K
Operating CF
-5.31 M
Total Assets
35.32 M
Total Liabilities
7.56 M
Equity
27.76 M
D/E Ratio
12,345
-3.76 %
Week
-3.76 %
1 Month
-36.95 %
3 Month
44.26 %
6 Month
-68.78 %
5 Year
-68.78 %
All Time
Cash Data
Cash Position
-
Monthly Burn
1.77 M
Runway
0 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
507.03 K
52 Week Range
0.87 - 3.19
% held by Insiders
16.56 %
% held by Institutions
21.63 %
Enterprise Value
43.41 M
Total Shares
60.79 M
Short %
8.08 %
Float Shares
42.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MAIA Biotechnology, Inc.
204Total events
12Upcoming
53Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 12
TBD
T2Trial Initiation
Advancement of at least one candidate into human clinical trials upon completion of GLP-toxicity studies
Event history 192
Jul 8, 2026
▲Topline ReadoutategansineClinical Data
Initial Part C efficacy data: 90.5% DCR in third-line NSCLC
non-small cell lung cancersource ↗
Jul 8, 2026
▲Enrollment CompleteategansineTrial
Completed international enrollment in Part C of THIO-101
non-small cell lung cancersource ↗
Q3 2026
▲Enrollment CompleteateganosineApprovedTrial
Phase 3 trial enrollment completion
non-small cell lung cancersource ↗
Jun 25, 2026
▲Enrollment CompleteategansineTrial
Completed international enrollment in Part C of Phase 2 THIO-101 expansion trial
non-small cell lung cancersource ↗
Jun 18, 2026
▲Enrollment UpdateateganosineApprovedTrial
Third U.S. clinical site (Winship Cancer Institute) activated and enrolling patients for Phase 2 expansion trial
non-small cell lung cancer (NSCLC)source ↗
Jun 10, 2026
▲Trial InitiationategenosineTrial
Phase 3 pivotal trial screening and enrollment ongoing
non-small cell lung cancer (NSCLC)source ↗
Jun 4, 2026
▲Enrollment UpdateategansineTrial
29 patients dosed among 34 activated trial sites in 6 foreign countries
non-small cell lung cancersource ↗
Jun 3, 2026
▲IND ClearanceategenosineIND
FDA cleared IND amendment to open U.S. enrollment for Phase 2 THIO-101 trial expansion
advanced non-small cell lung cancer (NSCLC)source ↗
Jun 3, 2026
◆Trial InitiationategenosineTrial
Phase 3 THIO-104 trial actively screening and enrolling patients
advanced non-small cell lung cancer (NSCLC)source ↗
Jun 2026
◆Enrollment UpdateategenosineTrial
Second U.S. clinical site expected to activate in coming weeks
advanced non-small cell lung cancer (NSCLC)source ↗
May 31, 2026
●Poster PresentationateganosineApprovedPresentation
Trial in Progress poster for THIO-104 at ASCO 2026
non-small cell lung cancersource ↗
Apr 16, 2026
▲First Patient DosedateganosineApprovedTrial
First U.S. site activated for Phase 2 THIO-101 expansion trial
advanced non-small cell lung cancer (NSCLC)source ↗
Drug Pipeline Intelligence
D30
Pipeline Score $41M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.5x
rNPV / MCap Top 35%
Micro Cap (rank 593 of 911)
Percentile RankMAIA Biotechnology, Inc. faces pipeline headwinds (30/100), with $1.9B risk-adjusted pipeline value, led by 6-Thio-2'-Deoxyguanosine in Carcinoma, Non-Small -Cell Lung (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6-Thio-2'-Deoxyguanosine Small molecule | Carcinoma, Non-Small -Cell Lung | Phase 3 | NCT06908304 | 80% | $1.9B | RECRUITING | 300 | STALLED | C (52) | Dec 31, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ateganosine Fast Track | advanced non-small cell lung cancer | Phase 2 | 2026-06-03 | overall survival (OS) beyond two years for eight patients treated with ateganosine in Parts A and B of THIO-101 Read More | MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion Read More | |
ateganosine Fast Track | advanced non-small cell lung cancer | Phase 2 | 2026-06-03 | overall survival (OS) beyond two years for eight patients treated with ateganosine in Parts A and B of THIO-101 Read More | MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion Read More | |
ateganosine Fast Track | advanced non-small cell lung cancer | Phase 2 | 2026-06-03 | overall survival (OS) beyond two years for eight patients treated with ateganosine in Parts A and B of THIO-101 Read More | MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MAIA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MAIA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MAIA▼ -1.4%today
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology reported promising initial efficacy data from its Phase 2 THIO-101 trial, showing a 90.5% disease control rate in advanced non-small cell lung cancer patients. The trial involved a heavily pre-treated population, and the results are consistent with earlier findings. The combination of ateganosine and cemiplimab demonstrates potential as a third-line therapy, significantly outperforming standard chemotherapy options.
Read more →MAIAMAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
MAIA Biotechnology has completed international enrollment in Part C of its Phase 2 THIO-101 trial, which evaluates ateganosine in advanced non-small cell lung cancer patients. The trial aims to assess the efficacy of ateganosine combined with cemiplimab in patients resistant to previous therapies. The FDA has granted Fast Track designation for ateganosine, potentially expediting its approval process.
Read more →MAIA▲ +6.1%on this news
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
MAIA Biotechnology has opened enrollment for its Phase 2 THIO-101 expansion trial at the Winship Cancer Institute, focusing on ateganosine as a treatment for non-small cell lung cancer. The trial aims to evaluate the efficacy and safety of ateganosine in patients resistant to previous therapies. Early results have shown promising survival rates, indicating potential for this novel agent in addressing unmet medical needs in lung cancer treatment.
Read more →MAIAMAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
MAIA Biotechnology has activated a second U.S. site for its Phase 2 THIO-101 expansion trial, aimed at treating non-small cell lung cancer (NSCLC) with ateganosine. This trial is part of a broader strategy to gather data that may support an accelerated FDA approval. The expansion includes multiple sites across the U.S., Europe, and Asia, enhancing patient enrollment efficiency.
Read more →MAIAMAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA Biotechnology has reported significant progress in its pivotal Phase 3 trial for ateganosine, a novel telomere-targeting therapy for advanced non-small cell lung cancer. With 29 patients dosed across 34 sites in six countries, the company aims to enroll up to 100 patients by year-end. The FDA has granted Fast Track designation for this promising treatment.
Read more →MAIA▲ +5.9%on this newsshared move
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
MAIA Biotechnology has received FDA clearance to expand U.S. enrollment in its Phase 2 THIO-101 trial for ateganosine, targeting advanced non-small cell lung cancer. The trial aims to assess the drug's efficacy in patients who have not responded to previous treatments. The company plans to activate additional clinical sites in the U.S. as part of this expansion.
Read more →MAIAMAIA Biotechnology Announces Open Market Purchases by CEO and Director
MAIA Biotechnology announced that CEO Vlad Vitoc and Director Stan Smith have increased their ownership through open market purchases. Dr. Vitoc purchased approximately 72,700 shares, while Dr. Smith acquired around 75,000 shares. Both executives expressed strong confidence in the company's telomere-targeting immunotherapy, ateganosine, which is in development for advanced non-small cell lung cancer.
Read more →MAIA▼ -6.5%on this newsshared move
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
MAIA Biotechnology presented a poster on its pivotal Phase 3 trial for ateganosine at ASCO 2026. The trial, THIO-104, aims to evaluate the drug's efficacy in treating third-line non-small cell lung cancer (NSCLC) patients resistant to current therapies. The first patient was dosed in December 2025, and enrollment is ongoing in Europe and Asia. The trial seeks to assess ateganosine's effectiveness compared to standard chemotherapy.
Read more →MAIA▼ -6.3%on this news
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer Exceptional measures of efficacy observed
MAIA Biotechnology has activated its first U.S. clinical site for the ongoing Phase 2 expansion trial of THIO-101, a novel telomere-targeting treatment for advanced non-small cell lung cancer (NSCLC). The trial aims to evaluate the efficacy of ateganosine, particularly in patients who have previously failed other cancer treatments. Initial findings indicate that this therapy may offer survival outcomes significantly better than current standard of care options. MAIA is set to expand the trial to four additional U.S. sites in 2026, while it is already ongoing in Europe and Asia with 44 active sites across six countries.
Read more →MAIAMAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy Strong participation in recent $33 million common stock offering high
MAIA Biotechnology has successfully raised $33 million through a capital offering, which is anticipated to fully finance its ongoing pivotal Phase 3 trial for ateganosine, a novel therapy aimed at treating non-small cell lung cancer (NSCLC). The company received FDA Fast Track designation for this therapy, which targets telomeres in cancer cells while also activating the immune system. Investor participation reflects strong confidence in the clinical program, with expectations for interim Phase 3 data to potentially support an early approval discussion with the FDA. This pivotal trial is designed to compare ateganosine’s efficacy against standard chemotherapy treatments in patients resistant to previous therapies.
Read more →MAIA▲ +6.9%on this news
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer Potential breakthrough therapeutic targets $50B+ global immunotherapy mar
MAIA Biotechnology announced promising results from its ongoing Phase 2 THIO-101 clinical trial for patients with non-small cell lung cancer. Eight patients treated with a combination of ateganosine and cemiplimab achieved overall survival rates that exceeded two years, significantly surpassing typical outcomes in their treatment lines. The data was presented at the European Lung Cancer Congress 2026, providing optimism for the future development of ateganosine as a novel immunotherapy agent in the market.
Read more →MAIAMAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
MAIA Biotechnology has successfully closed a public offering of 20 million shares at $1.50 each, raising $30 million. The offering was well-received, with participation from healthcare-focused investors. The funds will be utilized for clinical trials and general corporate needs. Additionally, underwriters have an option to purchase more shares.
Read more →MAIA▼ -27.1%on this newsshared move
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
MAIA Biotechnology has announced a proposed underwritten public offering of common stock and pre-funded warrants. The company aims to use the proceeds for clinical trials and general corporate purposes. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase additional shares. MAIA's focus remains on developing targeted immunotherapies for cancer.
Read more →MAIA▼ -27.1%on this newsshared move
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
MAIA Biotechnology has announced the pricing of a public offering of 20 million shares at $1.50 each, aiming to raise $30 million. The offering, which includes a 45-day option for underwriters to purchase additional shares, is set to close on March 4, 2026. Proceeds will be utilized for clinical trials and general corporate needs.
Read more →MAIA▲ +12%on this news
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
MAIA Biotechnology is advancing its Phase 3 clinical trial for ateganosine, a novel treatment for non-small cell lung cancer (NSCLC). The FDA has granted Fast Track designation, indicating a promising pathway for approval. The company aims to address the urgent need for effective therapies in the third-line treatment space, where current options are limited. CEO Vlad Vitoc highlights the potential of ateganosine to reshape cancer treatment paradigms.
Read more →MAIA▲ +6.4%on this news· ran to +19% by day 3
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
MAIA Biotechnology has reported significant advancements in its ateganosine treatment program for non-small cell lung cancer (NSCLC). The company has achieved FDA Fast Track designation, allowing for concurrent Phase 2 and Phase 3 trials. With promising efficacy data and a potential early commercial approval in sight, MAIA is positioned to make a substantial impact in the immunotherapy market.
Read more →MAIA▲ +8.8%on this news
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
MAIA Biotechnology announced that its board members participated in a recent private placement, purchasing a total of 179,737 shares, reflecting their confidence in the potential of ateganosine, an investigational treatment for non-small cell lung cancer (NSCLC). The company's pivotal Phase 3 trial has started, supported by a Fast Track designation from the FDA. The total gross proceeds of the offering were approximately $1.51 million. With the involvement of its directors, MAIA aims to strengthen its capability to advance its clinical programs.
Read more →MAIA▼ -8.9%on this news
MAIA Biotechnology Announces $1.51 Million Private Placement CHICAGO, IL
MAIA Biotechnology, Inc. has announced a private placement of 1,233,488 shares at a price of $1.224 per share, amounting to gross proceeds of approximately $1.51 million. The funding will be used to support the Phase II trial of THIO, a targeted immunotherapy aimed at treating non-small cell lung cancer. The deal is expected to close around December 18, 2025, pending customary closing conditions. Each share includes a warrant for additional stock at an exercise price of $1.36.
Read more →MAIA▲ +18.8%on this newsshared move
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology has initiated dosing in its THIO-104 Phase 3 pivotal trial for ateganosine, a treatment for advanced non-small cell lung cancer (NSCLC). The trial aims to compare ateganosine sequenced with a checkpoint inhibitor against chemotherapy in patients resistant to previous treatments. The company has received regulatory approval for patient screening in several countries and expects to support its case for FDA approval with robust data from this trial.
Read more →MAIA▲ +18.8%on this newsshared move
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
MAIA Biotechnology's leadership has shown confidence through recent insider purchases, acquiring approximately 182,445 shares. This move coincides with promising clinical results for ateganosine, a telomere-targeting therapy for advanced non-small cell lung cancer. The company's executives hold a significant share, reflecting their belief in the long-term potential of their innovative approach.
Read more →MAIA▲ +18.8%on this newsshared move
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
MAIA Biotechnology is introducing ateganosine, a telomere-targeting agent aimed at treating advanced non-small cell lung cancer (NSCLC) patients who do not respond to existing therapies. This innovative approach addresses a significant unmet need in the market, which is projected to grow substantially in the coming years. With Fast Track Designation from the FDA, MAIA is positioned to make a significant impact in oncology.
Read more →MAIA▲ +18.8%on this newsshared move
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
MAIA Biotechnology has initiated a pivotal Phase 3 trial for Ateganosine, a novel telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). The therapy exhibits promising early clinical results and has received Fast Track designation from the FDA, indicating potential for rapid development. This unique treatment differentiates itself through its dual mechanism of action, which could signify a new category in the oncology market. The company aims to establish Ateganosine as a leading option in next-generation cancer treatments, pending successful outcomes from ongoing clinical trials.
Read more →MAIAMAIA Biotechnology Announces Open Market Purchases by CEO and Directors
MAIA Biotechnology, Inc. recently announced that its CEO and several board members bought approximately 182,445 shares of the company's stock, indicating strong confidence in its future prospects. The purchases were made at an average price of $1.06 per share during late November 2025. The company's lead program, ateganosine, has shown promising results in a clinical trial for treating non-small cell lung cancer, with a response rate of 38% and an overall survival rate of 17.8 months. Board members expressed optimism about the company’s potential to improve cancer treatment outcomes and deliver value to shareholders.
Read more →MAIAMAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
MAIA Biotechnology presented updates on its ateganosine clinical program at SITC 2025, highlighting the enrollment of 12 patients in the Phase 2 THIO-101 expansion trial. The company also initiated patient screening for the Phase 3 THIO-104 trial, with promising survival rates noted in previous trials. The FDA has granted Fast Track designation for ateganosine in treating non-small cell lung cancer.
Read more →MAIA▼ -5.3%on this newsshared move
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation
MAIA Biotechnology has begun enrollment in Romania for its Phase 2 THIO-101 study of ateganosine, aimed at treating advanced non-small cell lung cancer (NSCLC). CEO Vlad Vitoc presented at the Smart Diaspora 2025 conference, highlighting the drug's promising response rates compared to existing treatments. The expansion of the study is part of MAIA's strategy to pursue accelerated FDA approval.
Read more →MAIAMAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
MAIA Biotechnology presented a Trial in Progress poster at the 2025 AACR-NCI-EORTC Conference, highlighting the enrollment of five patients in Part C of the THIO-101 Phase 2 trial. The trial aims to evaluate ateganosine's effectiveness in advanced non-small cell lung cancer (NSCLC) patients resistant to prior treatments. The company is expanding its trial locations to enhance patient recruitment and is optimistic about the treatment's potential benefits.
Read more →MAIA▲ +7.4%on this newsshared move
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
MAIA Biotechnology presented promising results from its ongoing Phase 2 clinical trial of ateganosine for non-small cell lung cancer (NSCLC) at the ESMO Congress 2025. A patient treated with ateganosine has achieved a remarkable 30-month survival, highlighting the drug's potential in a challenging treatment landscape. The trial aims to evaluate ateganosine's efficacy and safety in patients resistant to existing therapies.
Read more →MAIA▼ -6.4%on this news· ran to -18% by day 3
MAIA Biotechnology Announces $736,600 Private Placement
MAIA Biotechnology has announced a private placement of 603,769 shares at $1.22 each, raising approximately $736,600. The proceeds will be used to fund the Phase II trial THIO-101 and for working capital. The offering is set to close around October 15, 2025, pending customary conditions.
Read more →MAIAMAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
MAIA Biotechnology has announced a new digital asset treasury strategy, allowing up to 90% of its liquid assets to be held in cryptocurrencies like Bitcoin, Ethereum, and USD Coin. This initiative aims to diversify the company's investment portfolio while maintaining adequate working capital. The CEO emphasized a disciplined approach to selecting high-quality tokens. Additionally, a Digital Assets Advisory Board will be formed to oversee this strategy.
Read more →MAIAMAIA Biotechnology Announces $2.25 Million Private Placement CHICAGO, IL
MAIA Biotechnology, Inc. has announced a private placement for an aggregate of 1,733,766 shares of common stock at $1.30 per share, expecting to raise approximately $2.25 million. This investment will be directed towards funding the execution of the Phase II trial of its lead program, THIO. The private placement is set to close on or about October 1, 2025, pending customary closing conditions. The offered securities involve warrants that can be exercised at a later date, indicating a strategic approach to raising capital for ongoing research and development activities.
Read more →MAIAMAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
MAIA Biotechnology has received a $2.3 million grant from the NIH to expand its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). The trial aims to evaluate the efficacy of ateganosine as a third-line treatment for patients resistant to previous therapies. The funding will support patient enrollment in the U.S. over three years, enhancing the study's impact.
Read more →MAIA▲ +9%on this news
MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
MAIA Biotechnology has reported positive efficacy data from its Phase 2 clinical trial, THIO-101, for ateganosine in advanced non-small cell lung cancer (NSCLC). The trial demonstrated a progression-free survival of 5.6 months, significantly higher than the standard of care. The company is now enrolling patients for an expansion trial to further assess ateganosine's efficacy and safety.
Read more →MAIAMAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
MAIA Biotechnology announced that its abstract on ateganosine (THIO) has been selected for a poster presentation at the 2025 IASLC World Conference on Lung Cancer. The data highlights the drug's efficacy in treating non-small cell lung cancer (NSCLC), showing a median overall survival of 17.8 months. The FDA has granted Fast Track designation for ateganosine, facilitating its regulatory approval process.
Read more →MAIA▲ +7.1%on this news
MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
MAIA Biotechnology has published interim clinical data from its Phase 2 THIO-101 trial in the journal Cells. The study, authored by a team of researchers, highlights the potential of ateganosine, a telomere-targeting agent, in treating non-small cell lung cancer. The findings suggest promising results in overcoming resistance to conventional therapies.
Read more →MAIAMAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
MAIA Biotechnology has received a European patent for its ateganosine-based analogues, which are designed to target telomeres in cancer therapy. This patent covers methods of using ateganosine alone or in combination with checkpoint inhibitors. The company aims to enhance the specificity and efficacy of its cancer treatments, particularly for therapy-resistant cancers.
Read more →MAIAMAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatme
MAIA Biotechnology has received Fast Track designation from the FDA for ateganosine, a novel treatment targeting non-small cell lung cancer (NSCLC). The designation supports expedited development due to the drug's promising results in the pivotal Phase 2 THIO-101 clinical trial, which showed a median overall survival of 17.8 months in heavily pre-treated patients. Ateganosine is described as a first-in-class small molecule that disrupts telomere function in cancer cells, potentially offering a new therapeutic option in a market valued at $34 billion. The company anticipates a possible FDA decision on accelerated approval within the next year.
Read more →MAIAMAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy Manuscript featured in leading open-access peer-reviewed scientific journal
MAIA Biotechnology has announced the publication of preclinical data on its second generation ateganosine prodrugs in the journal Nucleic Acids Research. The study presents promising findings regarding the effectiveness of the prodrugs in enhancing cancer treatment and overcoming drug resistance. Notably, the lead compounds demonstrated significant anticancer efficacy and immune responsiveness in vivo. MAIA plans to advance these candidates into human clinical trials following necessary toxicity evaluations.
Read more →MAIA▲ +9.2%on this news
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer CHICAGO
MAIA Biotechnology has announced the dosing of the first patient in Taiwan as part of the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). This expansion is significant as it increases the patient pool and integrates locations in Europe and Asia. The trial evaluates ateganosine in patients who have not responded to previous treatments, with promising data showing improved overall survival rates. MAIA's CEO expressed optimism over positioning the company for success in a competitive oncology market projected to grow substantially by 2033.
Read more →MAIAMAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway CHICAGO
MAIA Biotechnology, Inc. has appointed prominent oncologists Claudia Fulgenzi and David J. Pinato to its Scientific Advisory Board to support a Phase 2 clinical trial focusing on hepatocellular carcinoma (HCC). These experts will provide insights on trial designs and protocols for the company's lead candidate, ateganosine. The company anticipates receiving necessary approvals to begin patient enrollment by year's end. In 2022, ateganosine was granted Orphan Drug Designation for HCC treatment, which may lead to market exclusivity for up to seven years.
Read more →MAIA▲ +8.4%on this newsshared move
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and e
MAIA Biotechnology has announced a master clinical supply agreement with Roche to explore the combination of its investigational drug, ateganosine, with Roche's atezolizumab for difficult-to-treat cancers. The partnership aims to advance clinical studies, highlighting the strong preclinical synergy observed between ateganosine and the PD-L1 inhibitor. This collaboration underscores MAIA's commitment to developing innovative immunotherapies in cancer treatment, particularly for non-small cell lung cancer patients. The agreement marks a significant step in MAIA's mission to offer new therapeutic options for patients who have not responded to existing treatments.
Read more →MAIA▲ +10.8%on this news
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data
MAIA Biotechnology announced a positive update from its THIO-101 Phase 2 clinical trial, revealing a median overall survival of 17.8 months for advanced non-small cell lung cancer patients treated with ateganosine. This represents a significant improvement over traditional chemotherapy options, which typically show survival of only 5 to 6 months. The treatment was well-tolerated among patients resistant to existing therapies. The company is optimistic about potentially expedited FDA approval, signaling a substantial shift in the NSCLC treatment landscape.
Read more →MAIACORRECTING and REPLACING: MAIA Biotechnology Announces $695,000 Private Placement This is a correction of the announcement. The number of shares and expected proceeds from the private placement have been corrected to 463
MAIA Biotechnology announced a correction regarding its private placement, detailing the issuance of 463,332 shares at $1.50 each, for total proceeds of approximately $695,000. The funds from this placement are intended to finance the Phase II trial of the drug candidate THIO. The offering is scheduled to close by May 29, 2025, pending customary closing conditions. The announcement also highlights potential risks associated with unregistered securities and the effects of dilution on existing shareholders.
Read more →MAIA▼ -6.8%on this news
MAIA Biotechnology Announces $1.08 Million Private Placement CHICAGO, IL
MAIA Biotechnology, Inc. has announced a $1.08 million private placement involving the sale of 719,999 shares of common stock at $1.50 each, combined with warrants for additional shares. This subscription is directed at accredited investors and certain company directors, with proceeds aimed to support the Phase II trial of their candidate drug THIO. The closing of this transaction is expected by May 7, 2025, pending standard conditions. This is a significant step for the company as it progresses in the development of targeted cancer therapies.
Read more →MAIAMAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO Nonproprietary drug name approval marks essential step in FDA approval process CHICAGO
MAIA Biotechnology announced the USAN Council's approval of 'ateganosine' as the nonproprietary name for its lead anticancer agent THIO, which is in clinical development for advanced non-small cell lung cancer (NSCLC). This designation is important as the company prepares for upcoming Phase 2 and 3 clinical trials. The drug, which utilizes an innovative mechanism targeting telomeres, has demonstrated potential in inducing tumor regression and activating immune responses. MAIA will maintain the THIO name for its clinical trial designations.
Read more →MAIA▲ +7.1%on this news
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients CHICAGO
MAIA Biotechnology has announced that it will initiate a Phase 3 pivotal trial, named THIO-104, to evaluate the efficacy of its investigational drug THIO combined with a checkpoint inhibitor in third-line treatment for advanced non-small cell lung cancer patients who are resistant to current therapies. This multicenter trial will involve around 300 patients and aims to compare THIO's effectiveness against chemotherapy. The initiation of this trial is a critical milestone for the company as it seeks FDA approval for THIO, which has shown promising results in earlier trials. Patient enrollment is expected to begin in the second half of 2025 across several countries.
Read more →MAIAMAIA Biotechnology Announces Non-Brokered Private Placement of approximately $1.43 million CHICAGO
MAIA Biotechnology, Inc. has announced a non-brokered private placement to raise approximately $1.43 million through the sale of 952,300 shares at $1.50 each. The company plans to utilize the proceeds for the Phase 2 clinical trial of THIO, aimed at treating cancer. The private placement is expected to close on February 26, 2025, and is part of a larger fundraising strategy including a previous $2.7 million placement.
Read more →MAIAMAIA Biotechnology Announces Private Placement of $2,715,000 CHICAGO
MAIA Biotechnology has announced the completion of a private placement agreement to raise $2,715,000 by selling 1,810,000 shares of common stock at a price of $1.50 per share. The offering includes warrants that allow investors to purchase additional shares at $1.87 each. The company plans to utilize the net proceeds for the costs associated with the Phase II trial of its cancer treatment THIO-101 and for general working capital purposes. The closing of the offering is expected around February 20, 2025, subject to customary closing conditions.
Read more →MAIA▲ +5.8%on this news
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer Median overall survival (OS) from THIO treatment extends to 16.9 months Newest data strengthens reg
MAIA Biotechnology announced promising updates from its Phase 2 THIO-101 trial, indicating that the median overall survival for patients with advanced non-small cell lung cancer (NSCLC) treated with THIO has reached 16.9 months. This efficacy data far surpasses the typical OS of 5 to 6 months achieved with standard chemotherapy. Additionally, MAIA sees potential for accelerated FDA approval based on the results of the ongoing trial, as THIO has demonstrated a strong safety profile in a heavily pre-treated patient population. The company is optimistic about the treatment's benefits for patients with limited therapeutic options.
Read more →MAIA▲ +10%on this news
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas CHICAGO
MAIA Biotechnology, Inc. announced that the FDA granted Rare Pediatric Disease designation for their drug THIO, aimed at treating pediatric-type diffuse high-grade gliomas. This designation is significant for the company as it enhances THIO's development and offers commercial incentives, including potential priority review vouchers upon future approval. THIO has shown promise in activating the immune system to combat treatment-resistant cancers in children, with previous research displaying its effectiveness in collaboration with Nationwide Children's Hospital.
Read more →MAIAMAIA Biotechnology Announces Private Placement of approximately $950,000 CHICAGO
MAIA Biotechnology, Inc. announced a private placement to raise approximately $950,000 by selling 507,364 shares of common stock at $1.872 each. Along with the shares, investors will receive warrants to purchase additional stock. The proceeds will be allocated towards funding Phase II clinical trials for THIO, a targeted cancer therapy, as well as for working capital. The private placement is set to close on or about December 11, 2024, pending customary closing conditions.
Read more →MAIA▲ +6.3%on this news
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Late breaking abstract to provide ne
MAIA Biotechnology announced that a late-breaking abstract regarding updates from its Phase 2 clinical trial of THIO-101 has been chosen for oral and poster presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting. The trial focuses on the combination therapy of THIO-101 with the checkpoint inhibitor cemiplimab in non-small cell lung cancer patients who have undergone multiple previous therapies. Preliminary data suggest THIO-101 provides significant therapeutic benefits and improved survival rates compared to existing treatments.
Read more →MAIAMAIA Biotechnology Announces $2.44 Million Private Placement CHICAGO
MAIA Biotechnology has announced a private placement to raise approximately $2.44 million by selling shares of common stock alongside warrants to accredited investors and company directors. The financing is intended to support the manufacturing of THIO, a cancer treatment undergoing Phase II clinical trials. Closing of the offering is expected on or about October 30, 2024, subject to standard conditions. The offering is being conducted under Regulation D and is not registered with the SEC, which limits its sale within the U.S.
Read more →MAIAMAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent THIO followed by cemiplimab shown to be well tolerated throughout trial, with far lower toxicity compared to standard of care tr
MAIA Biotechnology announced positive updates from its Phase 2 trial of THIO followed by cemiplimab for advanced non-small cell lung cancer (NSCLC). The trial showed that the treatment was well tolerated with substantially lower toxicity than standard options. Six patients have continued their regimen for over 12 months, demonstrating potential long-term benefits. MAIA emphasizes the potential of THIO as an effective treatment for patients who have exhausted standard therapies.
Read more →MAIAMAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent New science for cancer therapy drives powerful value proposition Exceptional measures of efficacy
MAIA Biotechnology has reported significant advancements in its Phase 2 clinical trial of THIO, a novel anticancer agent aimed at treating non-small cell lung cancer (NSCLC). Notably, THIO demonstrated a 38% overall response rate in patients who had previously received standard treatments, with a median progression-free survival of 5.5 months. The company has raised over $12 million this year, bolstering its research capabilities. Phase 2 trial data indicates the potential for THIO to redefine treatment standards in NSCLC, generating considerable interest from oncologists at recent medical conferences.
Read more →MAIA▼ -26.3%on this news· ran to -37% by day 1shared move
TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA June 2024 FORWARD-LOOKING STATEMENTS NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are forward-l
MAIA Biotechnology is focusing on dual mechanism of action telomere-targeting immunotherapies for cancer, with its lead candidate THIO-101 in a Phase 2 trial for non-small cell lung cancer (NSCLC). The drug has shown unprecedented disease control and a collaboration with Regeneron has been established for its use with Libtayo. MAIA reports multiple potential pathways to FDA approval, while cautioning that forward-looking statements about future performance come with risks and uncertainties. Upcoming clinical milestones include topline data expected in mid-2024 and long-term data in the second half of the year.
Read more →MAIA▲ +8.8%on this news· ran to +30% by day 3
MAIA Biotechnology Announces $1.00 Million Private Placement CHICAGO, IL
MAIA Biotechnology has announced a private placement of $1.00 million, issuing 494,096 shares of common stock at $2.034 per share to accredited investors and company directors. The proceeds from this offering will be used to fund research and development activities, particularly for the pivotal accelerated approval trial of its lead program, THIO, which targets non-small cell lung cancer. The transaction is expected to close on or about April 25, 2024, pending customary closing conditions.
Read more →MAIAMAIA Biotechnology Announces $1.33 Million Private Placement CHICAGO, IL
MAIA Biotechnology, Inc. announced a private placement of 578,643 shares of common stock, raising approximately $1.33 million to fund research and development initiatives. The company aims to utilize the net proceeds to support its THIO-101 trial in non-small cell lung cancer (NSCLC). The private placement is set to close around March 28, 2024, subject to customary conditions. The sale includes warrants for additional shares, providing investors with the opportunity for future equity in the company.
Read more →MAIAMAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, thi
MAIA Biotechnology reported promising results from its Phase 2 THIO-101 clinical trial, revealing a 38% overall response rate when combining the drug THIO with cemiplimab for patients with advanced non-small cell lung cancer (NSCLC). This outcome significantly outperforms the typical 6% response rate seen in standard third-line treatments. The study targeted patients who have exhausted other therapies and demonstrated that THIO could enhance tumor responses to immunotherapy. Safety profiles for the treatment remain consistent with earlier reports.
Read more →MAIAMAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbus
MAIA Biotechnology appointed Dr. Remus Vezan as a member of its Scientific Advisory Board. Dr. Vezan has extensive experience in oncology and immuno-oncology, having contributed to the approval of several notable therapies. His role is expected to guide MAIA as it moves towards the commercialization of its innovative cancer treatment, THIO. This investigational agent targets telomeres and is currently being developed for patients with Non-Small Cell Lung Cancer (NSCLC).
Read more →MAIAMAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer Topline data expected in second half of 2024 THIO-101 will be the first completed clinical study of a telomere tar
MAIA Biotechnology has successfully completed enrollment in its Phase 2 clinical trial for THIO-101, aimed at treating advanced non-small cell lung cancer (NSCLC). The trial, which enrolled 41 patients for a focus on the 180 mg dose, aims to evaluate the safety, tolerability, and efficacy of THIO combined with the immune checkpoint inhibitor cemiplimab. Preliminary results have indicated strong disease control and response rates, and the company anticipates topline data by the second half of 2024. This trial positions THIO as a potentially groundbreaking treatment for NSCLC.
Read more →MAIA▼ -9%on this newsshared move
March 2024 Dear fellow shareholders, At MAIA Biotechnology, our tenacious pursuit of innovative medicines to improve and extend people's lives with cancer has led us to the forefront of cancer research. As we wrap up the
MAIA Biotechnology has made significant progress in its Phase 2 clinical trial for THIO, a novel cancer treatment targeting non-small cell lung cancer (NSCLC). The trial, THIO-101, has shown promising results with above-average enrollment rates and remarkable disease control rates compared to standard treatments. Additionally, THIO has received three Orphan Drug Designations from the FDA, indicating its potential in treating multiple cancer types. The company anticipates more data updates in 2024 and is exploring accelerated approval pathways.
Read more →MAIAMAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds New patent would extend coverage and expand potential value of MAIA s telomere-targeting p
MAIA Biotechnology has published an international patent application for its dinucleotide compounds targeting telomeres in cancer cells. This application is expected to enhance the company's intellectual property protection globally and could significantly impact its telomere-targeting cancer therapies. The patent provides a potential avenue for first-in-class treatments, with preclinical studies already demonstrating anti-cancer efficacy in various models. The company aims to leverage this innovation as part of its broader strategy to improve cancer treatment outcomes.
Read more →MAIA▲ +20.3%on this news
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024 Lead candidate THIO maintains unprecedented disease control rates in Phase 2 non-small cel
MAIA Biotechnology reported promising interim results for its THIO-101 Phase 2 trial targeting non-small cell lung cancer (NSCLC). The company noted unprecedented disease control rates from the trial, which involved various dosing strategies. MAIA outlined key milestones for 2024, emphasizing the strength of its immunotherapy pipeline. Additionally, it received a third orphan drug designation for glioblastoma, expanding its focus on difficult-to-treat cancers.
Read more →MAIAMAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer Selected dose shows unprecedented disease control and overall response rates in a NSCLC clinical trial CHICAGO
MAIA Biotechnology announced the selection of a new dose for THIO-101, a Phase 2 clinical trial targeting advanced non-small cell lung cancer (NSCLC). The 180mg dosage of THIO demonstrated better efficacy and safety compared to other tested doses. Preliminary results indicate that patients showed significant disease control, exceeding initial targets. The company plans to pursue accelerated approval for THIO in the U.S. based on the trial's promising data.
Read more →MAIAFDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma Third orphan drug designation (ODD) granted to THIO by the FDA; drug also holds ODDs for hepatocellular carcinoma and smal
MAIA Biotechnology has announced that the FDA has granted orphan drug designation to its cancer treatment THIO for glioblastoma. This marks the third orphan drug designation for THIO, which also has designations for hepatocellular carcinoma and small cell lung cancer. The company's leadership expressed optimism about the drug's potential impact on glioblastoma patients, given the high mortality rate associated with the disease and the limited treatment options currently available. With ongoing Phase 2 trials for THIO in non-small cell lung cancer, MAIA aims to establish the efficacy of this novel therapy in treating challenging cancer types.
Read more →MAIAMAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO Substantial THIO program progress including unprecedented disease control rate (DCR) of
MAIA Biotechnology recently reported its financial results for the third quarter of 2023, highlighting significant progress in its THIO program. The company achieved a remarkable 100% disease control rate in second-line non-small cell lung cancer (NSCLC) during its Phase 2 trial, while expanding enrollment and receiving FDA clearance for trials in the U.S. Additionally, THIO demonstrated efficacy against aggressive gliomas and pediatric cancers. Despite a net loss of $4.9 million and reduced cash reserves, the overall clinical and operational updates reflect strong momentum for MAIA's lead asset in the oncology space.
Read more →MAIAMAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial Unprecedented disease control rat
MAIA Biotechnology announced promising preliminary efficacy data from its Phase 2 trial, THIO-101, for advanced Non-Small Cell Lung Cancer (NSCLC). The trial demonstrated a remarkable 100% disease control rate in second-line patients treated sequentially with THIO and cemiplimab. This success implies a potential breakthrough in treatment, considering the historical benchmarks for disease control rates. The trial focuses on patients who did not respond to or progressed after prior checkpoint inhibitor therapy.
Read more →MAIA▲ +11.8%on this news· ran to +46% by day 3
MAIA Biotechnology Announces Share Repurchase Program CHICAGO, IL
MAIA Biotechnology, Inc. has announced a share repurchase program authorized for up to $800,000 of its Class A common stock through September 2024. This initiative, approved by the Board of Directors, is intended to reflect the company's confidence in its market opportunities and long-term growth strategy. The shares may be repurchased via various methods, although there is no obligation to purchase any amount. The funding for the repurchase is expected to derive from cash on hand and anticipated future free cash flow.
Read more →MAIAMAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer Filed second provisional new composition of matter patent application for MA
MAIA Biotechnology reported its second quarter 2023 financial results, highlighting progress in its THIO-101 Phase 2 trial for Non-Small Cell Lung Cancer (NSCLC). The trial has seen promising preliminary survival data, with a high disease control rate among patients dosed. However, the company also reported an increased net loss compared to the previous year, raising questions about fiscal health. MAIA is actively expanding its clinical trial operations in Europe to bolster patient enrollment.
Read more →MAIAMAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer Of the first 11 patients with post-baseline scans, 9 met the disease control primary endpoint
MAIA Biotechnology has reported positive updates regarding its THIO-101 Phase 2 trial for advanced Non-Small Cell Lung Cancer. Out of the first 11 patients assessed, 9 achieved disease control, demonstrating an 82% success rate that surpasses typical outcomes for heavily pre-treated patients. This promising data supports previous pre-clinical findings that suggest THIO can enhance treatment efficacy when combined with immune checkpoint inhibitors. The trial is ongoing, and further monitoring will provide insights into the long-term effectiveness of the treatment.
Read more →MAIAMAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer First 2 patients dosed with THIO continue to be without documented progression for 12.2 a
MAIA Biotechnology has reported preliminary survival data from its THIO-101 Phase 2 trial for patients with advanced Non-Small Cell Lung Cancer (NSCLC). The first two patients treated with THIO in combination with cemiplimab have survived for 12.2 and 11.5 months, respectively, without documented disease progression. These results are promising as they suggest that THIO may help re-sensitize tumors to immune checkpoint inhibitors. The trial aims to confirm THIO's efficacy in patients who have previously failed multiple therapies.
Read more →MAIA▼ -9.4%on this news
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 has enrolled 29 patients CHICAGO, IL
MAIA Biotechnology has reported that its Phase II clinical trial, THIO-101, has successfully enrolled 29 patients, with additional sites opened in Hungary, Poland, and Bulgaria to facilitate enrollment. The trial is assessing the safety and efficacy of the investigational drug THIO in patients suffering from advanced Non-Small Cell Lung Cancer (NSCLC). MAIA anticipates an accelerated enrollment rate in Europe, targeting a total of 184 patients in the study. The trial will also evaluate the immune activation effects of THIO when administered before a checkpoint inhibitor.
Read more →MAIA▼ -6.7%on this news
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update Reported positive topline data from the completed Part A safety lead-in of the THIO-101 Phase 2 go-to-market trial in advanced
MAIA Biotechnology, Inc. reported its first quarter 2023 financial results, showcasing a positive trajectory for its THIO-101 Phase 2 trial, including favorable topline and preliminary survival data. The company commenced recruitment for Part B of the trial following the successful completion of Part A. Financially, MAIA raised approximately $5.75 million through a public offering but reported an increase in net loss compared to the previous year. The company continues to focus on developing THIO as a treatment for NSCLC and liver cancer.
Read more →MAIA▼ -7.8%on this news· ran to -22% by day 1
MAIA Biotechnology, Inc. Announces Pricing of Public Offering New York
MAIA Biotechnology, Inc. announced the pricing of a public offering of 2,222,200 shares at $2.25 per share, projected to raise around $5 million. The company plans to use the proceeds to advance ongoing clinical trials for its lead product, THIO, and for general corporate purposes. The offering is expected to close on April 27, 2023, subject to customary closing conditions. The SEC has approved the related registration statement, enabling the company to proceed with this capital raise.
Read more →MAIAMAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer CHICAGO
MAIA Biotechnology announced preliminary survival data from Part A of the THIO-101 Phase 2 trial, showing promising results for patients with advanced Non-Small Cell Lung Cancer (NSCLC). The first two patients continued to survive approximately 9-10 months after treatment initiation, both demonstrating no disease progression. The trial is currently in the safety lead-in stage and confirmed no dose limiting toxicities. These results offer hope as there are limited treatment options for patients who struggled with multiple prior therapies.
Read more →MAIAMAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models Study showed THIO with complete and durable responses in Hepatocellular Carcinoma (HCC), the dominant histology in primary liver cancer (90%)
MAIA Biotechnology announced the publication of a study in Molecular Cancer Therapeutics showcasing the potent anticancer activity of THIO in Hepatocellular Carcinoma (HCC) models. The research indicated that THIO activates the immune response and achieves significant tumor reduction. This finding supports plans for clinical trials assessing THIO's role in treating various cancers, particularly with existing immunotherapies. The company has already secured Orphan Drug Designation from the FDA for this indication.
Read more →MAIA▲ +6.1%on this news
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer CHICAGO
MAIA Biotechnology has reported encouraging topline results from the Part A safety lead-in of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). The safety data indicated that THIO, used in conjunction with Regeneron's anti-PD-1 therapy, Libtayo, was generally well-tolerated with few mild adverse effects observed. Following the successful completion of Part A, recruitment for Part B has begun, which will assess the efficacy and safe dose levels of THIO. The trial aims to evaluate THIO's potential as a second or later line treatment for NSCLC patients who have already undergone other therapies.
Read more →MAIA▲ +15.3%on this news
MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update Patient enrollment underway in Europe in ongoing Phase 2 trial in NSCLC (THIO-101) Outlined plan to initiate second Phase 2 Go-To-
MAIA Biotechnology, Inc. reported its full-year financial results for 2022, marking a net loss of approximately $15.7 million compared to $12.6 million in 2021. The company has initiated patient enrollment in Europe for its Phase 2 trial, THIO-101, and is planning to launch a second trial, THIO-102, for advanced NSCLC. Positive feedback from the FDA regarding its manufacturing and clinical development plans has also been received. The financials indicate an increase in research and development costs, driven primarily by trial preparations and operational expenses.
Read more →MAIAWest Lake Street, Suite 1700 | Chicago, IL 60606, USA www.maiabiotech.com | +1 (312) 416-8592 main MAIA BIOTECHNOLOGY's TelomerE-targeting Agent THIO, in combination with checkpoint inhibitor immune therapies Atezolizuma
MAIA Biotechnology announced the upcoming initiation of its second Phase 2 trial for THIO, a telomere-targeting agent, evaluating its efficacy in combination with immune checkpoint inhibitors pembrolizumab and atezolizumab across four cancer indications. The FDA has granted THIO Orphan Drug Designations for liver cancer and small cell lung cancer, highlighting its promising preclinical results. The trial aims to expand THIO's application to potentially over ten cancer indications, targeting high need patients. MAIA's strategy includes conducting the trial using an innovative design to optimize treatment combinations.
Read more →MAIAMAIA BIOTECHNOLOGY's TelomerE-targeting Agent THIO, in combination with checkpoint inhibitor immune therapies Atezolizumab (ANTI-PD-L1) or PEMBROLIZUMAB (anti-PD-1), Demonstrated S
MAIA Biotechnology has announced the initiation of its second Phase 2 trial for THIO, its telomere-targeting agent, in combination with checkpoint inhibitors pembrolizumab and atezolizumab. The FDA has granted Orphan Drug Designations for THIO based on promising preclinical data in liver and small cell lung cancer. This trial aims to evaluate the safety and efficacy of THIO across multiple cancer indications, potentially offering new treatment options for patients with limited therapies. MAIA's strategy focuses on adding more indications and combinations to enhance THIO's therapeutic potential.
Read more →MAIAMAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update Conducted an oral presentation covering the novel THIO platform at the XIV International Round Table on Nucleosides, Nucleotid
MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update CHICAGO - (BUSINESS WIRE) - November 9, 2022 -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted i
Read more →MAIAAll statements in this presentation, other than those relating to historical facts, are forward-looking statements. These forward-looking statements may include, but are not limited to, statements relating to our objecti
Telomere Targeting Immunotherapies for Cancer NYSE American: MAIA September 2022 Exhibit 99.1 All statements in this presentation, other than those relating to historical facts, are "forward-looking statements." These forward-looking statements may include, but are not limited
Read more →MAIA▲ +6.3%on this news
MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update CHICAGO
MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update CHICAGO - August 22, 2022 -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for
Read more →MAIAMAIA Biotechnology Announces Pricing of Initial Public Offering CHICAGO, IL
MAIA Biotechnology Announces Pricing of Initial Public Offering CHICAGO, IL, July 27, 2022--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pri
Read more →Competitive Position
How MAIA ranks across every disease it competes inCompetitive Position is a premium feature
See how MAIA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial